{name}
{subtitle}
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~17 mi. (Beuvry, France, +144 more cities)
facility
Clinique Ambroise Pare Beuvry ( Site 1213)
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002)
city
~17 mi. (Beuvry, France, +76 more cities)
facility
Clinique Ambroise Paré ( Site 1007)
drug
docetaxel, +1 more drug
drug type
chemotherapy, +1 more type
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~35 mi. (Lille, France, +93 more cities)
facility
Polyclinique du Bois ( Site 0458)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~35 mi. (Lille, France, +199 more cities)
facility
Hopital Claude Huriez CHRU LILLE ( Site 0440)
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~35 mi. (Lille, France, +207 more cities)
facility
Centre Oscar Lambret ( Site 0911)
biomarker
ER Positive, +1 more biomarker
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~35 mi. (Lille, France, +137 more cities)
facility
CHRU de Lille - Hopital Claude Huriez ( Site 0355)
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
city
~35 mi. (Lille, France, +201 more cities)
facility
CHRU Lille - Hopital Claude Huriez /ID# 220991
drug
azacitidine, +1 more drug
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
city
~35 mi. (Lille, France, +127 more cities)
facility
CHRU Lille - Hopital Claude Huriez /ID# 217916
drug
azacitidine, +2 more drugs
A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
city
~35 mi. (Lille, France, +197 more cities)
facility
CHRU Lille - Hopital Claude Huriez /ID# 217474
biomarker
BCR-ABL1 Fusion, +47 more biomarkers
drug
azacitidine, +1 more drug
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
city
~35 mi. (Lille, France, +156 more cities)
facility
CHRU Lille - Hopital Claude Huriez /ID# 202213
biomarker
IGH-CCND1 Fusion, +1 more biomarker
drug
dexamethasone, +1 more drug
drug type
chemotherapy, +1 more type